NasdaqGS:ACLXBiotechs
Assessing Arcellx (ACLX) Valuation After New Preclinical Data On BCMA CAR T Therapy Anito Cel
Arcellx (ACLX) shares are in focus after the company reported late breaking preclinical data on its BCMA directed CAR T therapy anitocabtagene autoleucel, highlighting its compact D Domain binder and potential safety differentiation.
See our latest analysis for Arcellx.
At a share price of $68.50, Arcellx has seen a 90 day share price return decline of 23.88%, while its year to date share price return of 8.15% and three year total shareholder return of 135.40% point to longer term momentum...